Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary hypogonadism associated with o,p' DDD (mitotane) therapy.

M Sparagana1

  • 1Medical and Research Services, Veterans Administration Hospital, Hines, Illinois 60141.

Journal of Toxicology. Clinical Toxicology
|January 1, 1987
PubMed
Summary

Mitotane, used for adrenocortical carcinoma, may harm the testes, causing impotence and testicular failure. Recovery of testicular function is possible after discontinuing the drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dosimetric determination of I-131 activity in the treatment of recurrent, nontoxic, multinodular goiter.

Clinical nuclear medicine·1993
Same author

Episodic ectopic ACTH syndrome associated with pulmonary infarctions.

Chest·1988
Same author

Positive iodine-131 6 beta-iodomethyl-19-norcholesterol (NP-59) adrenal images can precede return of adrenocortical function after o,p' DDD treatment.

Clinical nuclear medicine·1988
Same author

Late recurrence of benign pheochromocytomas: the necessity for long-term follow-up.

Journal of surgical oncology·1988
Same author

Tumor-induced osteomalacia: long-term follow-up of two patients cured by removal of their tumors.

Journal of surgical oncology·1987
Same author

An unusual pheochromocytoma associated with an androgen secreting adrenocortical adenoma. Evaluation of its polypeptide hormone, catecholamine, and enzyme characteristics.

Cancer·1987

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Mitotane is a drug primarily used for treating adrenocortical carcinoma due to its cytotoxic effects on the adrenal cortex.
  • Adrenocortical and testicular tissues share similarities, suggesting potential testicular toxicity from mitotane, though literature support is limited.

Observation:

  • A patient treated with mitotane for adrenocortical carcinoma developed impotence attributed to primary testicular failure.
  • Testicular biopsy revealed seminiferous tubule atrophy and maturation arrest, with normal Leydig cells, four months post-mitotane discontinuation.

Findings:

  • The patient experienced gradual improvement in libido and normalization of testosterone, gonadotropins, and LH response to GnRH over 4.5 years after mitotane cessation.
  • These observations suggest mitotane may possess cytotoxic properties affecting testicular function, similar to its known effects on the adrenal cortex.

Implications:

  • Mitotane's potential testicular toxicity warrants further investigation and consideration in patients undergoing treatment for adrenocortical carcinoma.
  • Understanding mitotane's effects on testicular function is crucial for managing potential side effects and monitoring patient recovery.

Related Experiment Videos